Johnson & Johnson Stock Performance
Johnson & Johnson shares closed at $269.99, reflecting a modest single-day decline of 0.38% per SID market data. Over the trailing three-month period, JNJ has gained 18.21%, significantly outpacing its one-month return of negative 1.25%, suggesting recent short-term consolidation following a strong rally. On a twelve-month basis, the stock has appreciated 27.61%, underscoring sustained upward momentum. Technically, JNJ trades above both its 50-day moving average of $263.29 and its 200-day moving average of $243.95, positioning the stock in a confirmed uptrend according to Massive/Polygon data. The 14-day relative strength index stands at 53.0, indicating neutral momentum without overbought or oversold conditions. JNJ's beta of 0.349 reflects substantially lower volatility relative to the broader market. Average daily trading volume registers at approximately 8.82 million shares, supporting adequate liquidity for the company's $505.8 billion market capitalization.
Johnson & Johnson Valuation Analysis
Johnson & Johnson currently trades at a price-to-earnings ratio of 20.30, positioning it within a moderate valuation range for the Healthcare sector per SID market data. The PEG ratio stands at 1.91, indicating that the stock's earnings growth rate does not fully justify its P/E multiple on a growth-adjusted basis, as values above 1.0 generally suggest relatively full pricing. JNJ's price-to-book ratio of 6.43 reflects a significant premium to book value, consistent with the company's extensive intangible asset base and brand portfolio according to SEC filings. The dividend yield registers at 2.45%, providing income-oriented investors with a meaningful cash return component. With a market capitalization of approximately $505.8 billion, Johnson & Johnson remains one of the largest companies in the global healthcare space. These valuation metrics collectively suggest the stock is priced at a premium reflective of its defensive characteristics and consistent earnings profile.
Smart Money Activity for JNJ
Johnson & Johnson's composite smart money score stands at 50 out of 100, generating a neutral signal per SID market data. The institutional component scores a perfect 25 out of 25, reflecting strong and sustained institutional ownership conviction in the stock. In contrast, the insider trading component registers at just 4.6 out of 25, driven by a notable imbalance in insider transactions. According to SEC Form 4 filings, there have been 14 insider trades over the past 90 days, comprising 4 purchases and 10 sales, indicating that company insiders have been net sellers during this period. The dark pool activity score of 9.3 out of 25 suggests moderate but unremarkable institutional block trading activity. Congressional trading activity scores 11.2 out of 25 based on 13F institutional filings and congressional disclosure data. The divergence between maximum institutional confidence and relatively elevated insider selling creates a mixed signal that warrants monitoring, particularly as the stock trades near its recent highs.
Johnson & Johnson Earnings Outlook
Johnson & Johnson has demonstrated consistent earnings execution across recent quarters per company earnings reports. In the most recent reported quarter ending January 2026, JNJ posted earnings per share of $2.46, narrowly missing the consensus estimate of $2.47 by one cent, representing a surprise of negative 0.41%. The company rebounded in the subsequent quarter with EPS of $2.70 versus estimates of $2.67, delivering a positive surprise of $0.03. The July 2026 quarter showed continued upside, with actual EPS of $2.90 exceeding the $2.85 consensus by $0.05, marking the strongest beat in the sequence. Looking ahead, analyst estimates project EPS of $2.57 for the quarter reporting on October 13, 2026. The sequential earnings trajectory from $2.46 to $2.70 to $2.90 demonstrates an upward trend in quarterly profitability, reflecting operational momentum across Johnson & Johnson's diversified healthcare portfolio.
Wall Street Analyst Ratings for JNJ
Wall Street consensus on Johnson & Johnson remains decidedly constructive, with all five most recent analyst actions reaffirming bullish ratings per Wall Street analyst reports. On September 10, 2026, HSBC maintained its Buy rating, followed by UBS reiterating Buy on September 2. Guggenheim reiterated its Buy recommendation on August 6, while Wells Fargo maintained its Overweight rating on August 3. Guggenheim issued an additional Buy reiteration on July 17 according to SID consensus data. Notably, none of the recent analyst actions involved downgrades or initiations at neutral or underperform levels, reflecting broad institutional confidence in JNJ's fundamental trajectory. The uniformity of positive sentiment across major global banks including HSBC, UBS, Guggenheim, and Wells Fargo is notable given the stock's 27.61% twelve-month appreciation. The sustained bullish coverage suggests analysts view current valuation levels as supported by Johnson & Johnson's earnings growth profile and diversified healthcare revenue streams.
